Baird raised the firm’s price target on Alignment Healthcare (ALHC) to $22 from $17 and keeps an Outperform rating on the shares. The firm sees minimal incremental buyers of stocks in the managed care and healthcare facilities group until the policy overhang clears. Baird does not not expect guidance raises as it believes companies will maintain 2025 “conservatism and cushion” given potential Part D and macro headwinds that may evolve later this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Morning Movers: Stock futures rebound following days of dips
- Alignment Healthcare price target raised to $23 from $18 at Stifel
- Alignment Healthcare, Sutter Health renew long-term, strategic collaboration
- Alignment Healthcare management to meet with Stephens
- Alignment Healthcare price target raised to $18.50 from $15.50 at BofA